Top Analyst Upgrades and Downgrades: BioMarin, CSX, Kinder Morgan, Microsemi, Splunk, US Steel, Walmart and More

Print Email

The stock market fell handily on the first day of March after steel and aluminum tariffs sparked fears of a trade war, and the major indexes were indicated lower on Friday as well. While investors had to witness aggressive and violent selling in early February, the trend that prevailed was for investors to buy the pullback. That being said, this bull market is now a few days away from being nine years old. Investors have to decide how they want to be positioned for the rest of 2018 and beyond.

24/7 Wall St. reviews dozens of analyst research reports each day of the week to find new ideas for investors and traders alike. Some analyst and research reports cover stocks to buy. Others cover stocks to sell or to avoid.

Additional color and commentary has been added on most of the daily analyst reports. The consensus analyst price targets and other valuation metrics are from the Thomson Reuters sell-side research service.

These were the top analyst upgrades, downgrades and other research calls from Friday, March 2, 2018.

Allegheny Technologies Inc. (NYSE: ATI) was raised to Buy from Neutral with a $32 price objective (versus a $25.61 prior close) at Merrill Lynch. The firm noted that recent stock weakness on its joint venture concerns does offer an opportunity for investors.

American Outdoor Brands Corp. (NYSE: AOBC) was maintained as Outperform but the price target was cut from $15 to $13 (versus a $9.41 close) at Wedbush Securities.

Ameriprise Financial Inc. (NYSE: AMP) was downgraded to In-Line from Outperform with a $170 price target (versus a $153.66 close) at Evercore ISI.

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) was reiterated as Outperform and the price target was raised to $116 from $113 (versus a $77.67 close, after a 4.3% drop) at Credit Suisse.

BP Midstream Partners L.P. (NYSE: BPMP) was reiterated as Buy and the price target was raised to $24 from $21 (versus a $19.56 close) at UBS.

Brunswick Corp. (NYSE: BC) was reiterated as Outperform with a $70 price target (versus a $60.91 close) at Wedbush. The firm is still positive now that the fitness spin-off has been confirmed and will offer a chance for management to focus on its core operations.

CSX Corp. (NYSE: CSX) was maintained as Outperform but the price target was cut to $65 from $67 at Credit Suisse. Shares closed up 1.5% at $54.52 on Thursday.

Kinder Morgan Inc. (NYSE: KMI) was maintained as Buy at UBS, but the price target was lowered to $26 from $28. Kinder Morgan was up one cent at $16.21 on Thursday, and its shares were down 1% at $16.05 on Friday.

Magellan Midstream Partners L.P. (NYSE: MMP) was reiterated as Buy and the price target was raised to $81 from $80 (versus a $63.10 close) at UBS.

Manitowoc Co. Inc. (NYSE: MTW) was downgraded to Neutral from Outperform with a $33 price target (versus a $27.95 close, after a 6% drop) at Robert W. Baird. The shares were indicated down 2.8% more at $27.15 on Friday morning.

Medical Transcription Billing Corp. (NASDAQ: MTBC) was started as Buy with a $5 price target (versus a $3.67 close, after a 7.3% drop) at H.C. Wainwright.

Follow @Jonogg on Twitter to receive the daily analyst calls and other market research calls directly on your feed.